The safety of statins in children

Acta Paediatrica, International Journal of Paediatrics

Volumn 102, Issue 9, 2013, Pages 857-862

  Lamaida, Norman ^a   Capuano, Ernesto ^a   Pinto, Laura ^a   Capuano, Eduardo ^a   Capuano, Rocco ^a   Capuano, Vincenzo ^a  

^a Department of Cardiology   (Italy)

Author keywords

Children; HMG CoA reductase inhibitors; Safety

Indexed keywords

ATORVASTATIN; ERYTHROMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ABDOMINAL PAIN; BLURRED VISION; CHILD SAFETY; CHILDHOOD DISEASE; COCHRANE LIBRARY; CREATINE KINASE BLOOD LEVEL; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FAMILY HISTORY; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRANSAMINASEMIA; INFLUENZA; MEDLINE; MENORRHAGIA; METABOLIC DISORDER; MORBIDITY; MORTALITY; MYALGIA; MYOPATHY; NAUSEA; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; RHINOPHARYNGITIS; RISK FACTOR; SEXUAL DEVELOPMENT; SEXUAL MATURATION; SIDE EFFECT; SYSTEMATIC REVIEW;

CHILDREN; HMG-COA REDUCTASE INHIBITORS; SAFETY;

ADOLESCENT; AGE FACTORS; CARDIOVASCULAR DISEASES; CHILD; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIFE STYLE; MALE; PATIENT SAFETY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 84881312244     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/apa.12280     Document Type: Review

References (30)

1. Braamskamp M, Wijburg FA, Wiegman A,. Drug therapy of hypercholesterolaemia in children and adolescents. Drugs 2012; 72: 759-72.
2. Lebenthal Y, Horvarth A, Dziechciarz P, Szajewska H, Shamir R,. Are treatment targets for hypercholesterolemia evidence based? Systematic review and meta-analysis of randomized controlled trials. Arch Dis Child 2010; 95: 673-80.
3. Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newbuger JW, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart association Expert Panel on Population and Prevention Science. Circulation 2006; 114: 2710-38.
4. Daniels SR, Greer FR,; Committee on nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics 2008; 122: 198-208.
5. Eiland LS, Luttrell PK,. Use of statins for dyslipidemia in the pediatric population. J Pediatr Pharmacol Ther 2010; 15: 160-72.
6. Belay B, Belamarich PF, Tom-Revzon C,. The use of statins in pediatrics: knowledge base, limitations, and future directions. Pediatrics 2007; 119: 370-80.
7. De Ferranti S, Ludwig DS,. Storm over statins-the controversy surrounding pharmacologic treatment of children. N Engl J Med 2008; 359: 1309-12.
8. National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for cardiovascular Health and risk reduction in children and adolescents. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 (Suppl 5): S213-56.
9. Reiner Z, Catapano AL, De Backer G, Taskinen MR, Wiklund O, Agewall S, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur J Heart 2011; 32: 1769-818.
10. De Jongh S, Lilien MR, Roodt J, Stroes ES, Bakker HD, Kastelein JJ,. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2117-21.
11. Capuano V, Rocco A, Lamaida N, Capuano E,. il trattamento dell'ipercolesterolemia nei bambini: necessità e preoccupazioni. G.Ital.cardiol. 2011; 12: 707-16.
12. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
13. Armitage J,. The safety of statins in clinical practice. Lancet 2007; 370: 1781-90.
14. McCrindle BW,. Hyperlipidemia in children. Thromb Res 2006; 118: 49-58.
15. de Jongh S, Ose L, Szamosi T, Gagne C, Lambert M, Scott R, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 2002; 106: 2231-7.
16. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Buller HL, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004; 292: 331-7.
17. Knipscheer HC, Boelen CC, Kastelein JJ, van Diermen DE, Groenemeijer BE, van den Ende A, et al. Short term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 1996; 39: 867-71.
18. Clauss SB, Holmes KW, Hopkins P, Stein E, Cho M, Tate A, et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics 2005; 115: 688.
19. Stein EA, Illingworth DR, Kwiterovich PO Jr, Liacouras CA, Siimes MA, Jacobson MS, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 1999; 281: 137-43.
20. McCrindle BW, Ose L, Marais AD,. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 2003; 142: 74-80.
21. Avis HJ, Hutten BA, Gagné C, Langslet G, McCrindle BW, Wiegman A, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 2010; 55: 1121-6.
22. Federal Drugs Authority. (2010). Available from: www.fda.gov.
23. O'Gorman CS, O'Neill M, Conwell L,. Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits. Vasc Health Risk Manag 2011; 7: 1-14.
24. Arambepola C, Farmer AJ, Perera R, Neil HA,. Statin treatment for children and adolescents with heterozygous familial hypercholesterolemia: a systematic review and meta-analysis. Atherosclerosis 2007; 195: 339-47.
25. Avis HJ, Vissers Mn, Stein EA, Wijburg FA, Trip MD, Kastelein JJ, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007; 27: 1803-10.
26. Vuorio A, Kuoppola J, Kovanen PT, Humphries Se, Strandberg T, Tonstad S, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 2010; 7: CD006401.
27. Cannioto Z, Tamburlini G, Marchetti F,. Statins for children? A word of caution. Eur J Clin Pharmacol 2009; 65: 217-8.
28. Iughetti L, Bruzzi P, Predieri B,. Evaluation and management of hyperlipidemia in children and adolescents. Curr Opin Pediatr 2010; 22: 485-93.
29. Psaty BM, Rivara FP,. Universal screening and drug treatment of dyslipidemia in children and adolescents. JAMA 2012; 307: 257-8.
30. Stein EA,. Statins and children: whom do we treat and when? Circulation 2007; 116: 594-5.